|
Liver carcinoma
|
0.310 |
Biomarker
|
disease |
BEFREE |
Cholesterol attenuated the progression of DEN-induced hepatocellular carcinoma via inhibiting SCAP mediated fatty acid de novo synthesis.
|
30638930 |
2019 |
|
Liver carcinoma
|
0.310 |
Biomarker
|
disease |
CTD_human |
Dietary alpha-linolenic acid reduces COX-2 expression and induces apoptosis of hepatoma cells.
|
14563831 |
2004 |
|
Diabetes Mellitus, Experimental
|
0.200 |
Biomarker
|
disease |
RGD |
Differential gene expression pattern of diabetic rat retinas after intravitreal injection of erythropoietin.
|
20973890 |
2011 |
|
Hypercholesterolemia
|
0.200 |
Biomarker
|
disease |
RGD |
Modified HMG-CoA reductase and LDLr regulation is deeply involved in age-related hypercholesterolemia.
|
16741953 |
2006 |
|
Arteriosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
SCAP knockdown in vascular smooth muscle cells alleviates atherosclerosis plaque formation via up-regulating autophagy in ApoE<sup>-/-</sup> mice.
|
30462530 |
2019 |
|
Atherosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
SCAP knockdown in vascular smooth muscle cells alleviates atherosclerosis plaque formation via up-regulating autophagy in ApoE<sup>-/-</sup> mice.
|
30462530 |
2019 |
|
Arteriosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Effect of Tetramethylpyrazine on Atherosclerosis and SCAP/SREBP-1c Signaling Pathway in ApoE<sup>-/-</sup> Mice Fed with a High-Fat Diet.
|
28491104 |
2017 |
|
Atherosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Effect of Tetramethylpyrazine on Atherosclerosis and SCAP/SREBP-1c Signaling Pathway in ApoE<sup>-/-</sup> Mice Fed with a High-Fat Diet.
|
28491104 |
2017 |
|
Arteriosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Both SREBP-2 and SCAP are candidates to contribute to the development of atherosclerosis.
|
16466730 |
2006 |
|
Atherosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Both SREBP-2 and SCAP are candidates to contribute to the development of atherosclerosis.
|
16466730 |
2006 |
|
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
What's more, downregulation of SCAP could weaken the cancer-promoting effects of estrogen on BC.
|
31360104 |
2019 |
|
Metabolic Diseases
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Increased hepatic INSIG-SCAP-SREBP expression is associated with cholesterol metabolism disorder in assisted reproductive technology-conceived aged mice.
|
30562550 |
2019 |
|
Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our study reveals a previously unrecognized negative feedback loop in SCAP/SREBP-1 signaling mediated by miR-29 and suggests that miR-29 treatment may represent an effective means to target GBM.
|
27477273 |
2016 |
|
Metabolic Syndrome X
|
0.020 |
Biomarker
|
disease |
BEFREE |
We explored the association between the variants of the sterol-regulatory element-binding transcription factor-1 (SREBF1) gene and the SREBP cleavage-activation protein (SCAP) gene with AAP-induced MetS in a genetic case-control study.
|
26982812 |
2016 |
|
Metabolic Syndrome X
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Effect of an SNP in SCAP gene on lipid-lowering response to rosuvastatin in Indian patients with metabolic syndrome.
|
27885915 |
2016 |
|
Glioblastoma Multiforme
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our study reveals a previously unrecognized negative feedback loop in SCAP/SREBP-1 signaling mediated by miR-29 and suggests that miR-29 treatment may represent an effective means to target GBM.
|
27477273 |
2016 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Targeting SCAP N-glycosylation may provide a promising means of treating malignancies and metabolic diseases.
|
26555173 |
2015 |
|
Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Xenograft studies reveal that blocking SCAP N-glycosylation ameliorates EGFRvIII-driven glioblastoma growth.
|
26555173 |
2015 |
|
Metabolic Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
Targeting SCAP N-glycosylation may provide a promising means of treating malignancies and metabolic diseases.
|
26555173 |
2015 |
|
Glioblastoma Multiforme
|
0.020 |
Biomarker
|
disease |
BEFREE |
Xenograft studies reveal that blocking SCAP N-glycosylation ameliorates EGFRvIII-driven glioblastoma growth.
|
26555173 |
2015 |
|
Malignant neoplasm of urinary bladder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, Targeting SCAP may provide a promising means of treating BC and a new perspective for the tumorigenesis of bladder cancer.
|
31360104 |
2019 |
|
Bladder Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, Targeting SCAP may provide a promising means of treating BC and a new perspective for the tumorigenesis of bladder cancer.
|
31360104 |
2019 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
Accordingly, targeting of SREBP-2 with Fatostatin which specifically inhibits SCAP (SREBP cleavage-activating protein) and prevents SREBP activation, attenuated breast cancer-induced osteolysis in vivo.
|
30394316 |
2019 |
|
B-Cell Lymphomas
|
0.010 |
Biomarker
|
group |
BEFREE |
Meanwhile, SCAP revealed a protective effects on the liver injury-related enzymes and factors, such as significantly diminished malondialdehyde (MDA) levels and glutathione (GSH) depletion, reduced ratio of B-cell lymphoma-2 (Bcl-2)-associated X protein (Bax)/Bcl-2, prohibited cleaved caspase-3 expression, and elevated the expression of p-AMPK, p-Akt, p-glycogen synthase kinase 3β (GSK 3β), nuclear factor erythroid 2-derived-like 2 (Nrf 2) and heme oxygenase-1 (HO-1) proteins in the liver tissues of the mouse model.
|
31400930 |
2019 |
|
Adult Liver Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
RA-XII Suppresses the Development and Growth of Liver Cancer by Inhibition of Lipogenesis via SCAP-dependent SREBP Supression.
|
31083642 |
2019 |